Jubilant Therapeutics has received the US Food and Drug Administration (FDA) clearance for the Investigational New Drug application (IND) to start a Phase I/II clinical trial of JBI-778 to treat solid tumours.

The therapy is intended for treating solid tumours with brain metastases and primary brain tumours including high-grade glioma.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The open-label, two-part dose escalation and expansion trial will analyse the safety profile, pharmacokinetics, optimal dosing and initial activity of JBI-778. 

Subjects with stable brain metastasis whose disease did not respond to previous prior standard therapy will be part of the dose escalation phase.

Patients with active brain metastases and high-grade gliomas will be included in the expansion cohorts.

JBI-778 is an oral brain penetrant and selective inhibitor of protein arginine methyl transferase 5 (PRMT5). 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As against current PRMT5 inhibitors, it has a mechanism of action by being substrate-competitive and S-adenosylmethoinine (SAM) cooperative.

This mechanism along with an improved brain exposure facilitates targeting of both primary brain tumours and CNS metastasis. 

JBI-778 is said to be the second, highly selective oral drug candidate of the company to enter clinics. 

Jubilant Therapeutics CEO Syed Kazmi said: “JBI-778 was engineered by our drug discovery team to be a PRMT5 substrate-competitive and brain penetrant drug candidate to address primary brain tumours and brain metastases which currently have limited treatment options. 

“In addition to JBI-778, we are also advancing an oral brain penetrant PDL1 inhibitor, JBI 2174, which is on the IND-track to potentially treat primary CNS cancers among others.”

In April this year, the company dosed the first subject in a Phase I/II trial of JBI-802 in advanced solid tumour patients.